14
Aug
2020

Share

Optum – a hidden gem in US healthcare

It is no secret that healthcare expenditure in the United States is an outlier compared to other similar countries. And, similar to much of the rest of the developed world, demand for healthcare in the US will only accelerate as the baby boomers continue to retire en masse. Today, there are approximately 55 million US citizens over the age of 65 years old. By 2030, there will be approximately 75 million.

Screen Shot 2020-08-13 at 12.35.40 pm

A solution to deliver more effective healthcare, more intelligently and efficiently is so desperately needed. And hidden inside the largest health insurer in the US, UnitedHealth Group, is a technology platform business, with positive network effects, that is quietly bringing about this solution. That business is called Optum.

Introduction to Optum

Optum is a capital-light, technology-enabled health services business leveraging distinctive capabilities in data and analytics, pharmacy care services, population health, health care delivery and health care operations. Its three segments are: (i) OptumHealth; (ii) OptumInisght; and (iii) OptumRx, as illustrated below.

Screen Shot 2020-08-13 at 12.36.09 pm

We view Optum as a platform that directly delivers healthcare to nearly 100 million members in an increasingly effective and efficient way, on behalf of both UnitedHealthcare (UnitedHealth’s own health insurance business) and more than 80 third-party payers. Optum leverages insights from data, as well as the “value-based-care” philosophy of risk-sharing with its own primary care providers, including its 52 thousand physicians, to drive better outcomes.

Just a few weeks ago, the company described how Optum nurses were meeting the increasing need for infusion services in the comfort and safety of people’s homes – a trend which is growing double-digits per annum. According to UnitedHealth, home infusion visits by Optum’s nurses result in fully equivalent clinical efficacy, greater patient convenience and satisfaction, and reduced risk to immuno-compromised patients. And importantly, delivering infusion services this way can be delivered at up to one-half the cost of traditional settings.

Optum’s flywheel to success

We believe Optum’s advantages will only strengthen over time, thanks to the positive, self-reinforcing network effects associated with its business. As illustrated below, Optum uses its scale and data to deliver healthcare at a lower cost on behalf of its largest client, UnitedHealthcare, and its many other third-party payers. By delivering healthcare more efficiently and effectively, outcomes are better, patients are more satisfied, and payers can increase their premiums at slower rates – thereby, increasing market share. As more third-party payers partner with Optum, its scale builds and its flywheel gathers speed.

Screen Shot 2020-08-13 at 12.36.38 pm

At the heart of Optum’s advantage is data, as it is for so many of the world’s great businesses today. We believe Optum has a clear data advantage in the US healthcare industry, and this advantage is growing. Optum sources data in a number of ways, including: from payers – especially UnitedHealthcare, the country’s largest insurer; through its own primary data collections – for example, when nurses visit patients at home, they also collect significant environmental data; and patient data via its physician network – also the largest in the country. And this patient data is key. It contains the clinical data that is critical to derive learnings around efficacy and preventative care opportunities. It is perhaps no surprise, therefore, that Optum has been acquiring physician networks aggressively in recent years.

A long-term investment opportunity

Over the longer-term, the Optum flywheel is targeting the very large areas of healthcare expenditure in the US, such as chronic disease care. This is critical given those suffering chronic disease drive a disproportionate share of healthcare spend. As the company disclosed last year: the 30 million people in the US with three or more chronic diseases account for two-thirds of healthcare spending today, and the number of people is expected to grow to 80 million by 2030.

Today, the revenue per member in OptumHealth is around $20 per month – not much more than a Netflix subscription. Last year, the CEO of UnitedHealth said that, in the extreme and over many decades, this number could get up to $900-1000 per month!

This is a multidecade growth story. And one that we believe is not being fully appreciated by the market. This misperception is perhaps a consequence of Optum – a capital-light business, being mixed in with UnitedHealthcare – a more capital intensive business. Over time, as the contribution from Optum continues to grow, we believe the market will start to realise the true potential of this platform.

We are delighted to announce the launch of the Montaka Global Extension Fund (Quoted Managed Hedge Fund) (ASX: MKAX). This new fund gives investors access to a portfolio of global growth opportunities through one online trade. You can also register to receive more information about the fund here: MKAX: Register Your Interest

The Montgomery Global Funds and Montaka own shares in UnitedHealth. This article was prepared 13 August with the information we have today, and our view may change. It does not constitute formal advice or professional investment advice. If you wish to trade UnitedHealth you should seek financial advice.

Our Funds

The Montgomery Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montgomery Global Fund

  • GLOBAL
  • Concentrated high conviction equities
  • From $25,000
Learn More

Montaka Global Access Fund

  • GLOBAL
  • Access long/short global equity portfolio
  • From $50,000
Learn More

Montgomery Global Equities Fund (ASX:MOGL)

  • GLOBAL
  • Concentrated high conviction equities
  • No minimum investment - see your broker limits
Learn More

Montgomery Small Companies Fund

  • AUSTRALIA/NZ
  • Concentrated high conviction equities
  • From $25,000
Learn More
Close

Our Funds

Concentrated High Conviction Equities

Listed

Montgomery Global Equities Fund (ASX:MOGL)

Global
Available on the ASX as an Exchange Traded Managed Fund, invests in 15 to 30 quality global businesses for long-term capital growth with a target distribution yield of 4.5% per annum. Mirrors the strategy of the Montgomery Global Fund.
Unlisted From $25,000

Montgomery Global Fund

Global
Invests in 15 to 30 quality global businesses for long-term capital growth. Priced daily. Mirrors the strategy of the Montgomery Global Equities Fund (ASX:MOGL).
Unlisted from $25,000

The Montgomery Fund

Australia/NZ
Aims to provide long-term growth and income by investing in 20 to 40 high-quality Australian and New Zealand businesses trading at attractive valuations. Priced daily.
UNLISTED FROM $25,000

Montgomery Small Companies Fund

Australia/NZ
Aims to provide long-term growth by investing in 30 to 50 high quality, undervalued, Australian and NZ small and emerging companies with strong growth potential. Priced daily.
Unlisted from $1 Million

The Montgomery [Private] Fund

Australia/NZ
Seeks to deliver absolute returns from a portfolio of high-quality Australian and New Zealand businesses. Capital preservation is paramount. By invitation only.

Alternate Equity Strategies

New Fund

Montaka Global Extension Fund (ASX: MKAX)

GLOBAL
An ASX-quoted managed fund, typically, the Fund seeks to hold 15 to 30 long positions and partially offsets these with 10 to 40 short positions, operating with 130% exposure to its long portfolio and 30% exposure to its short portfolio, resulting in a net market exposure of around 100%. Features a target distribution yield of 5% per annum.
Unlisted from $50,000

Montaka Global Access Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. Priced monthly. Provides retail investors access to the Montaka Global Fund.
Unlisted from $1million

Montaka Global 130/30 Fund

Global
Provides the opportunity to benefit from both the gains of extraordinary businesses and the declines of deteriorating businesses through a global equity active extension strategy, which has the potential to significantly outperform the broader equities market over time. Seeks to generate double-digit annual average returns, net of fees. Daily priced.
Unlisted From $1 Million

Montaka Global Fund

Global
Aims to generate materially higher risk-adjusted returns, net of fees, than is generally available in the equities market over the medium term. By invitation only.